BioPharmSignal logoBioPharmSignal

Biotech News

Supernus Announces Third Quarter 2026 Financial Results

Supernus (SUPN)SupernusEarnings

Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026, representing an increase of 29% compared to the same period last year.

Related news

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

XERSXeris Pharmaceuticals2026-11-05 12:00 EST

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

NBIXNeurocrine Biosciences2026-11-02 21:49 EST

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

ALKSAlkermes plc2026-11-03 12:05 EST

Alkermes plc Reports Third Quarter 2026 Financial Results

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

ECORelectroCore2026-10-29 12:00 EST

electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026

ABOSAcumen Pharmaceuticals2026-10-26 11:00 EST

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

TNXPTonix Pharmaceuticals2026-10-26 11:00 EST

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

View all latest news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

SUPNSupernus2026-11-02 14:18 EST

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

SUPNSupernus2026-10-29 20:05 EST

Supernus Announces Third Quarter 2026 Financial Results

SUPNSupernus2026-10-28 12:30 EST

Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign

SUPNSupernus2026-10-21 23:45 EST

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

Stock data

Close
26.74 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States